Chris Ryan

3 weeks ago | onclive.com | Chris Ryan

The addition of eftilagimod alpha (efti; IMP321) to pembrolizumab (Keytruda) and chemotherapy led to high rates of responses and disease control in the first-line treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC), according to data from the INSIGHT-003 trial, which is stratum C in the phase 1 INSIGHT study (NCT03252938).1 Findings announced by Immutep showed that as of the May 6, 2025, data cutoff, patients in the overall population of...

3 weeks ago | onclive.com | Chris Ryan

The FDA has approved the VENTANA MET (SP44) RxDx Assay for use as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with high c-MET protein overexpression who may be candidates for treatment with telisotuzumab vedotin-tllv (Emrelis).1The VENTANA MET (SP44) RxDx Assay is an immunohistochemistry (IHC) assay designed to detect c-MET expression based on the percentage of tumor cells stained and the intensity of the staining.

3 weeks ago | onclive.com | Chris Ryan

The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) harboring high c-MET protein overexpression who have received a prior systemic therapy.

3 weeks ago | onclive.com | Chris Ryan

The FDA has approved belzutifan (Welireg) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. The regulatory decision was supported by findings from the phase 2 LITESPARK-015 trial (NCT04924075), which showed that patients achieved an overall response rate (ORR) of 26% (95% CI, 17%-38%). The median duration of response (DOR) was 20.4 months (95% CI, 8.3-not reached).

3 weeks ago | onclive.com | Chris Ryan

Generic, AB-rated formulations of eltrombopag (Promacta) as an oral suspension and a tablet are now commercially available for the treatment of select patients with severe aplastic anemia and immune thrombocytopenia.1,2 Specifically, the generic oral suspension and tablet formulations of eltrombopag are approved in the following indications: For patients with severe aplastic anemia who are insufficiently responsive to immunosuppressive therapy For patients 1 year of age and older with...